Drug Information for TAZORAC (tazarotene) Gel 0.05%(tazarotene) Gel 0.1% (Allergan, Inc.): WARNINGS

Ads
  • Pregnancy Category X. See CONTRAINDICATIONS section. Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when TAZORAC® Gel is used. The possibility that a woman of childbearing potential is pregnant at the time of institution of therapy should be considered. A negative result for pregnancy test having a sensitivity down to at least 50 mIU/mL for hCG should be obtained within 2 weeks prior to TAZORAC® Gel therapy, which should begin during a normal menstrual period.

  • Drug Information Provided by National Library of Medicine (NLM).
Ads